Prevention of Chemotherapy-Induced Cardiotoxicity in High-Risk Patients

This study has been completed.
Information provided by:
European Institute of Oncology Identifier:
First received: February 15, 2006
Last updated: NA
Last verified: January 2006
History: No changes posted
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.

Condition Intervention Phase
Chemotherapy-Induced Cardiotoxicity Revealed by TnI Increase.
Drug: oral enalapril
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Prevention

Resource links provided by NLM:

Further study details as provided by European Institute of Oncology:

Primary Outcome Measures:
  • Incidence of chemotherapy-induced cardiotoxicity

Secondary Outcome Measures:
  • Major adverse cardiac events, including death.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All

Inclusion Criteria:

  • Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I

Exclusion Criteria:

  • Contraindication to ACE-inhibitors
  • On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00292526

European Institute of Oncology
Milan, Italy, 20141
Sponsors and Collaborators
European Institute of Oncology
Study Director: Carlo M Cipolla, MD European Institute of Oncology
Principal Investigator: Daniela Cardinale, MD European Institute of Oncology
  More Information

Publications: Identifier: NCT00292526     History of Changes
Other Study ID Numbers: IEO S67/500 
Study First Received: February 15, 2006
Last Updated: February 15, 2006

Keywords provided by European Institute of Oncology:
Chemotherapy-induced cardiotoxicity
Heart failure

Additional relevant MeSH terms:
Pathologic Processes
Drug-Related Side Effects and Adverse Reactions
Chemically-Induced Disorders
Radiation Injuries
Wounds and Injuries
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents processed this record on January 19, 2017